share_log

bluebird bio | 8-K: Current report

bluebird bio | 8-K: Current report

bluebird bio | 8-K：重大事件
美股SEC公告 ·  11/06 16:24

Moomoo AI 已提取核心信息

On November 6, 2024, bluebird bio, Inc. conducted its 2024 Annual Meeting of Stockholders, where several key proposals were voted upon. The stockholders elected John O. Agwunobi, Elisabeth Leiderman, and Andrew Obenshain as Class II directors. Additionally, the stockholders approved the amendment and restatement of the 2023 Incentive Award Plan, increasing the number of shares authorized for issuance by 15 million to a total of 20.2 million. The compensation paid to the company's named executive officers was approved in a non-binding advisory vote. However, the proposal to amend the Certificate of Incorporation for officer exculpation did not receive the required votes for approval. The selection of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024, was ratified. A proposal to adjourn the Annual Meeting to solicit additional proxies for the approval of certain proposals was also passed. The meeting was adjourned with respect to a proposal for a reverse stock split, with the reconvened meeting scheduled for December 4, 2024.
On November 6, 2024, bluebird bio, Inc. conducted its 2024 Annual Meeting of Stockholders, where several key proposals were voted upon. The stockholders elected John O. Agwunobi, Elisabeth Leiderman, and Andrew Obenshain as Class II directors. Additionally, the stockholders approved the amendment and restatement of the 2023 Incentive Award Plan, increasing the number of shares authorized for issuance by 15 million to a total of 20.2 million. The compensation paid to the company's named executive officers was approved in a non-binding advisory vote. However, the proposal to amend the Certificate of Incorporation for officer exculpation did not receive the required votes for approval. The selection of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024, was ratified. A proposal to adjourn the Annual Meeting to solicit additional proxies for the approval of certain proposals was also passed. The meeting was adjourned with respect to a proposal for a reverse stock split, with the reconvened meeting scheduled for December 4, 2024.
2024年11月6日，蓝鸟生物公司进行了2024年股东年会，就几项重要提案进行了投票。股东选举了John O. Agwunobi、Elisabeth Leiderman和Andrew Obenshain担任二类董事。此外，股东批准了对2023年激励奖计划的修订和重签，将授权发行的股份数量从1500万增加到总共2020万。公司董事会为公司指定的执行官支付的报酬经过了一项不具约束力的咨询投票获得批准。然而，用于官员免责的公司章程修正提案未获得批准所需的投票。审议安永会计师事务所(Ernst & Young LLP)作为截至2024年12月31日的财政年度独立注册的会计师的选择得到批准。提议为推动某些提案的批准而将年会延期以征求额外委托人的公函也已通过。就逆向股票拆分提案，会议被推迟，重新召开的会议定于2024年12月4日举行。
2024年11月6日，蓝鸟生物公司进行了2024年股东年会，就几项重要提案进行了投票。股东选举了John O. Agwunobi、Elisabeth Leiderman和Andrew Obenshain担任二类董事。此外，股东批准了对2023年激励奖计划的修订和重签，将授权发行的股份数量从1500万增加到总共2020万。公司董事会为公司指定的执行官支付的报酬经过了一项不具约束力的咨询投票获得批准。然而，用于官员免责的公司章程修正提案未获得批准所需的投票。审议安永会计师事务所(Ernst & Young LLP)作为截至2024年12月31日的财政年度独立注册的会计师的选择得到批准。提议为推动某些提案的批准而将年会延期以征求额外委托人的公函也已通过。就逆向股票拆分提案，会议被推迟，重新召开的会议定于2024年12月4日举行。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间